Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant

Phase 4 Unknown 4 enrolled University of Wuerzburg Pfizer · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate changes in left ventricular mass and cardiac function in patients with active acromegaly before and after treatment with the growth hormone receptor antagonist pegvisomant for one year.

Timeline

Start: 2006-06
Primary completion: —
Completion: 2010-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pegvisomant	Protein / enzyme biologic	10 mg	Subcutaneous

Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant

Summary

Timeline

Drugs

Indications